Trial
NCT04628481
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Dompé Farmaceutici S.p.A
Collaborators
—
Condition
Recent Onset type1 Diabetes
Intervention
Ladarixin
Why stopped
The study was stopped due to futility as per protocol
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-17